Positive News Sentiment NASDAQ:OMGA Omega Therapeutics - OMGA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.77 +0.01 (+0.13%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.52▼$7.8050-Day Range$4.75▼$10.9552-Week Range$1.98▼$14.31Volume22,743 shsAverage Volume81,997 shsMarket Capitalization$373.34 millionP/E RatioN/ADividend YieldN/APrice Target$8.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Omega Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside12.6% Upside$8.75 Price TargetShort InterestBearish1.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$160,000 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.12) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector765th out of 1,055 stocksBiological Products, Except Diagnostic Industry122nd out of 170 stocks 2.4 Analyst's Opinion Consensus RatingOmega Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.75, Omega Therapeutics has a forecasted upside of 12.6% from its current price of $7.77.Amount of Analyst CoverageOmega Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.84% of the float of Omega Therapeutics has been sold short.Short Interest Ratio / Days to CoverOmega Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Omega Therapeutics has recently increased by 3.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOmega Therapeutics does not currently pay a dividend.Dividend GrowthOmega Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMGA. Previous Next 3.8 News and Social Media Coverage News SentimentOmega Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Omega Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for OMGA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omega Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $160,000.00 in company stock.Percentage Held by Insiders60.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.69% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Omega Therapeutics are expected to decrease in the coming year, from ($2.12) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omega Therapeutics is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omega Therapeutics is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmega Therapeutics has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Omega Therapeutics (NASDAQ:OMGA) StockOmega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to target specific epigenomic loci within insulated genomic domains from genome-wide DNA-sequences with single or multiple genes to treat and cure diseases through Precision Genomic Control. The company is advancing a pipeline of development candidates covering a range of disease areas, including oncology, regenerative medicine, multigenic diseases, and select monogenic diseases. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More Receive OMGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OMGA Stock News HeadlinesJanuary 17, 2023 | finance.yahoo.comOmega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers SymposiumJanuary 10, 2023 | finance.yahoo.comOmega Feeders introduces a new cattle feedlotJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 8, 2022 | finance.yahoo.comKSQ Appoints Mahesh Karande to its Board of DirectorsNovember 28, 2022 | finance.yahoo.comWall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 136%: Read This Before Placing a BetNovember 17, 2022 | finance.yahoo.comOmega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 15, 2022 | finance.yahoo.comOmega Therapeutics Named One of BioSpace's 2023 Best Places to WorkNovember 11, 2022 | finance.yahoo.comWall Street Analysts Believe Omega Therapeutics, Inc. (OMGA) Could Rally 229%: Here's is How to TradeJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 10, 2022 | finance.yahoo.comShareholders in Omega Therapeutics (NASDAQ:OMGA) have lost 79%, as stock drops 13% this past weekNovember 8, 2022 | finance.yahoo.comOmega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsNovember 3, 2022 | finance.yahoo.comOmega Therapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 2, 2022 | finance.yahoo.comOmega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular CarcinomaOctober 27, 2022 | finance.yahoo.comOmega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC OncogeneSeptember 26, 2022 | finance.yahoo.comOmega Therapeutics to Participate in Two Upcoming Investor ConferencesSeptember 6, 2022 | finance.yahoo.comOmega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 1, 2022 | finance.yahoo.comOmega Therapeutics Announces Appointment of Rainer Boehm to its Board of DirectorsAugust 4, 2022 | finance.yahoo.comOmega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressAugust 3, 2022 | finance.yahoo.comOmega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare ConferenceJuly 15, 2022 | seekingalpha.comOmega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002July 14, 2022 | finance.yahoo.comOmega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular CarcinomaJuly 11, 2022 | finance.yahoo.comOmega Therapeutics, Inc. (NASDAQ:OMGA) is up 28%, but insiders still continue to see a loss of US$692k on their US$952k investmentJune 30, 2022 | finance.yahoo.comOmega Therapeutics Touts Encouraging Preclinical Data In Liver Cancer Animal ModelsJune 30, 2022 | finance.yahoo.comOmega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal CancerJune 23, 2022 | finance.yahoo.comOmega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal CancerJune 15, 2022 | msn.comOmega Therapeutics Submits IND For Liver Cancer CandidateJune 15, 2022 | finance.yahoo.comOmega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular CarcinomaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OMGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OMGA Company Calendar Last Earnings11/08/2022Today1/27/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OMGA CUSIPN/A CIK1850838 Webwww.omegatherapeutics.com Phone617-949-4360FaxN/AEmployees79Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.75 High Stock Price Forecast$12.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+12.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,280,000.00 Net Margins-6,252.80% Pretax Margin-6,253.54% Return on Equity-55.11% Return on Assets-45.58% Debt Debt-to-Equity Ratio0.15 Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$140,000.00 Price / Sales2,666.72 Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book1.85Miscellaneous Outstanding Shares48,049,000Free Float19,220,000Market Cap$373.34 million OptionableNot Optionable Beta0.59 Key ExecutivesDr. Noubar B. Afeyan Ph.D. (Age 59)Co-Founder & Chairman Comp: $36.42kMr. Mahesh Karande (Age 49)Pres, CEO & Board Director Comp: $1.04MDr. Thomas McCauley (Age 53)Chief Scientific Officer Comp: $588.5kMr. Joshua Reed M.B.A. (Age 49)Chief Financial Officer Dr. Sivakesava Sakhamuri Ph.D.Sr. VP and Head of Technical Operations & QualityMs. Ling Zeng Esq. (Age 53)J.D., Chief Legal & Admin. Officer and Sec. Mr. Kevin McManus (Age 54)Chief HR Officer Ms. Barbara Y. Chan (Age 58)Sr. VP of Fin. Mr. Charles O'Donnell Ph.D.VP and Head of Computational Genomics & Data SciencesDr. Yan Moore M.D. (Age 55)Chief Medical Officer More ExecutivesKey CompetitorsC4 TherapeuticsNASDAQ:CCCCVigil NeuroscienceNASDAQ:VIGLVoyager TherapeuticsNASDAQ:VYGRIcosavaxNASDAQ:ICVXMeiraGTxNASDAQ:MGTXView All CompetitorsInsiders & InstitutionsRichard A YoungSold 20,000 sharesTotal: $160,000.00 ($8.00/share)Vanguard Group Inc.Bought 241,526 shares on 11/15/2022Ownership: 2.063%BlackRock Inc.Sold 39,262 shares on 11/15/2022Ownership: 1.368%Platinum Investment Management Ltd.Sold 63,352 shares on 11/15/2022Ownership: 1.313%State Street CorpBought 8,100 shares on 11/15/2022Ownership: 0.083%View All Insider TransactionsView All Institutional Transactions OMGA Stock - Frequently Asked Questions Should I buy or sell Omega Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares. View OMGA analyst ratings or view top-rated stocks. What is Omega Therapeutics' stock price forecast for 2023? 4 analysts have issued twelve-month price targets for Omega Therapeutics' shares. Their OMGA share price forecasts range from $4.00 to $12.00. On average, they expect the company's stock price to reach $8.75 in the next year. This suggests a possible upside of 12.6% from the stock's current price. View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts. How have OMGA shares performed in 2023? Omega Therapeutics' stock was trading at $5.71 at the start of the year. Since then, OMGA stock has increased by 36.1% and is now trading at $7.77. View the best growth stocks for 2023 here. When is Omega Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our OMGA earnings forecast. How were Omega Therapeutics' earnings last quarter? Omega Therapeutics, Inc. (NASDAQ:OMGA) announced its earnings results on Tuesday, November, 8th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.09. The firm earned $0.60 million during the quarter. Omega Therapeutics had a negative trailing twelve-month return on equity of 55.11% and a negative net margin of 6,252.80%. When did Omega Therapeutics IPO? (OMGA) raised $126 million in an initial public offering on Friday, July 30th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. What is Omega Therapeutics' stock symbol? Omega Therapeutics trades on the NASDAQ under the ticker symbol "OMGA." How do I buy shares of Omega Therapeutics? Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Omega Therapeutics' stock price today? One share of OMGA stock can currently be purchased for approximately $7.77. How much money does Omega Therapeutics make? Omega Therapeutics (NASDAQ:OMGA) has a market capitalization of $373.34 million and generates $140,000.00 in revenue each year. The company earns $-68,280,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. How can I contact Omega Therapeutics? Omega Therapeutics' mailing address is 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.omegatherapeutics.com. The company can be reached via phone at 617-949-4360 or via email at argotomega@argotpartners.com. This page (NASDAQ:OMGA) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.